Product Information
FLUTICASONE-SALMETEROL 55-14 is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $114.8490 per EA under NDC 00093360782. Its NADAC has been published 442 times since Apr 18, 2018.
FDA first approved this application on Jan 27, 2017.
Strength
55; 14 ug/1; ug/1
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00093360782
Classification
Generic
Dosage Form
POWDER, METERED
Route
RESPIRATORY (INHALATION)
Effective Date
9/23/2026
Active Ingredients
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATEApproval Type
Authorized Generic (NDA)
FDA Application
NDA208799FDA Approved
1/27/2017
On Market Since
4/28/2017
Pharmacological Classes
Price Statistics
The NADAC for FLUTICASONE-SALMETEROL 55-14 has been published 442 times since Apr 18, 2018, and over the history we have for it it has risen 27.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $114.8490 per EA |
|---|---|
| All-time high | $114.8490 (Sep 30, 2026) |
| All-time low | $83.3740 (Jan 23, 2019) |
| 52-week high | $114.8490 |
| 52-week low | $108.1785 |
| Median price | $101.1539 |
| Average price | $98.2421 |
| Largest weekly change | +21.0% (Apr 20, 2022) |
| Weeks tracked | 442 |
| Tracking since | Apr 18, 2018 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Fluticasone Propionate and Salmeterol market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Fluticasone Propionate and Salmeterol market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Corticosteroid class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of FLUTICASONE-SALMETEROL 55-14?
The current National Average Drug Acquisition Cost (NADAC) for FLUTICASONE-SALMETEROL 55-14, manufactured by Teva Pharmaceuticals USA Inc., is $114.8490 per EA (NDC 00093360782), effective Sep 30, 2026.
How has the price of FLUTICASONE-SALMETEROL 55-14 changed over time?
Over the history we have for it, the NADAC for FLUTICASONE-SALMETEROL 55-14 has risen 27.0%. It has been tracked across 442 weekly CMS publications since Apr 18, 2018.
What are the highest and lowest recorded NADAC prices for FLUTICASONE-SALMETEROL 55-14?
Since Apr 18, 2018, the NADAC for FLUTICASONE-SALMETEROL 55-14 has ranged from a low of $83.3740 (Jan 23, 2019) to a high of $114.8490 (Sep 30, 2026), with a median of $101.1539 per EA.
Are there cheaper alternatives to FLUTICASONE-SALMETEROL 55-14?
No other NADAC-published product currently shares the active ingredient and strength of FLUTICASONE-SALMETEROL 55-14 in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures FLUTICASONE-SALMETEROL 55-14?
FLUTICASONE-SALMETEROL 55-14 (NDC 00093360782) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.